Shareholders can consider booking profits on their holdings in Dr Reddy’s Laboratories (DRL). The stock has since our last ‘buy’ recommendation gained over 60 per cent. While a strong set of numbers in the just-ended December quarter, potential exclusivity revenues from products such as Prilosec OTC, Allegra D24 and Arixtra and the likely expansion in market reach through its alliance with GSK promise growth potential, the stock appears to have priced in most of these potential positives.
Tags: Dr. Reddy's Laboratories, Dr. Reddy's Laboratories analysis, Dr. Reddy's Laboratories share, Dr. Reddy's Laboratories stock